Sitagliptin Phosphate Monohydrate CAS 654671-77-9 Puritas >99.0% (HPLC) API Factory High Quality

Description:

Chemical Name: Sitagliptin Phosphate Monohydrate

CAS: 654671-77-9

Puritas: >99.0% (HPLC in fundamento exsiccato)

Aspectus: Alba ad Off-White Crystalline pulveris

Curatio generis II diabete mellitus

API High Quality, Commercial Production

E-Mail: alvin@ruifuchem.com

Mitte ad nos inscriptio

Product Detail

Product Tags

Descriptio:

Supple Sitagliptin Phosphate Monohydratorum intermedia:
Sitagliptin API CAS 486460-32-6
Sitagliptin Phosphate Monohydratum API CAS 654671-77-9
Acidum trifluorophenylaceticum 2,4,5-
Boc-(R)-3-Amino-4-(2,4,5-Trifluoro-Phenyl)-Butyric Acidum CAS 486460-00-8
Sitagliptin Triazole Hydrochloride CAS 762240-92-6
Sitagliptin Phosphate Monohydratum Intermediate CAS 486460-21-3

Chemical Properties:

Nomen chemicum	Sitagliptin Phosphate Monohydrate
Synonyma	(R) -3-amino-1-(3-(trifluoromethyl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)-4- phosphate monohydrate
CAS Number	654671-77-9
Stock Status	In Stock, Productio Ascendite ad Tons
Formulae hypotheticae	C16H20F6N5O6P
M. Pondus	523.3240802
Liquescens punctum	202.0~204.0℃
Aqua Solubility	Solutum in aqua
Imprimis Rotationes	-18.0°~-23.0° (C=I, Aqua)
Brand	Ruifu Chemical

Specifications:

Item	Specifications
Aspectus	Alba ad Off-White Crystalline pulveris
Lepidium sativum ab HPLC	Retention tempus specimen concordat cum reference vexillum
IR-Infrared Imaginum	IR Absorptio Imaginis sample concordabit cum spectro normali
Phosphate	Obsequitur
Puritas / Analysis Methodus	> 99.0% (HPLC in exaruit basis)
Aqua Content (KF)	3.3%~4.4%
Residere in Ignition	≤0.20%
Sulphate	≤0.04%
Chloride	≤0.05%
Chiral immunditia	<0.50%
Substantiae cognatae
una immunditia	<0.50%
Totalis immunditias	<1.0%
Ethyl Acetate	<0.50%
Metalla gravis	<20ppm
Test Standard	Enterprise Standard
Consuetudinem	Pharmaceutical intermedia

Sarcina & Repono:

sarcina: Utrem, aluminium foil, sacculum, 25kg/cardboard Drum, vel secundum exigentiam emptoris.

Repono Condition:Repone in vasis signatis in loco frigido et sicco;A luce et humore protege.

commoda:

FAQ:

Applicatio:

Sitagliptin Phosphate Monohydratorum (CAS: 654671-77-9), novum medicamentum ad curationem diabete generis 2 .Mense Augusto 2009 pharmacum ab Unione Europaea probatum est tamquam medicamentum primae lineae pro curatione speciei 2 diabete.Sitagliptin Phosphate primus est FDA-probatus dipeptidylus peptidase-IV inhibitor adhibendus in tractatione speciei 2 diabete longe, sub commercii nomine Januvia.Dipeptidylpeptidase Ⅳ (DPP-Ⅳ) celerius et efficaciter detractat GLP-1, GLP-I, quae est efficacissima stimulator productionis et secretionis insulinae, inhibitio ergo DPP-IV partes endogenosae GLP-1 augere potest, sanguinem augens. insulinum gradus, ita reducere et conservare sanguinem GLYCOSA aequat in aegris diabeticis.In praesenti medicina confirmavit DPP-IV inhibitorem novum genus medicamentorum anti-diabetici esse, et eventus clinicos demonstrant medicinae effectum bonum hypoglycemicum habere.Quia GLP-1 dependens partes glucose-dependens agit in productione et secretione insulina promovenda, motus communes adversas sicut hypoglycemia et lucrum pondus causatum ex usu medicamentorum antidiabeticorum non occurrunt.